DSpace Repositorium (Manakin basiert)

Multiple sclerosis progression: time for a new mechanism-driven framework

Zur Kurzanzeige

dc.contributor.author Kuhlmann, Tanja
dc.contributor.author Moccia, Marcello
dc.contributor.author Coetzee, Timothy
dc.contributor.author Cohen, Jeffrey A.
dc.contributor.author Graves, Jennifer
dc.contributor.author Marrie, Ruth Ann
dc.contributor.author Montalban, Xavier
dc.contributor.author Yong, V. Wee
dc.contributor.author Thompson, Alan J.
dc.contributor.author Reich, Daniel S.
dc.contributor.author Correale, Jorge
dc.contributor.author International Advisory Committee on Clinical Trials in Multiple Sclerosis
dc.date.accessioned 2022-12-07T12:06:14Z
dc.date.available 2022-12-07T12:06:14Z
dc.date.issued 2022-11-18
dc.identifier.citation Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289-7. doi: 10.1016/S1474-4422(22)00289-7. Epub ahead of print. PMID: 36410373. es_ES
dc.identifier.uri https://doi.org/10.1016/s1474-4422(22)00289-7
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/725
dc.description.abstract Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for patient care, research, and regulatory approval of medications. Accumulating evidence suggests that the clinical course of multiple sclerosis is better considered as a continuum, with contributions from concurrent pathophysiological processes that vary across individuals and over time. The apparent evolution to a progressive course reflects a partial shift from predominantly localised acute injury to widespread inflammation and neurodegeneration, coupled with failure of compensatory mechanisms, such as neuroplasticity and remyelination. Ageing increases neural susceptibility to injury and decreases resilience. These observations encourage a new consideration of the course of multiple sclerosis as a spectrum defined by the relative contributions of overlapping pathological and reparative or compensatory processes. New understanding of key mechanisms underlying progression and measures to quantify progressive pathology will potentially have important and beneficial implications for clinical care, treatment targets, and regulatory decision-making. es_ES
dc.language.iso eng es_ES
dc.publisher Lancet Pub. Group es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Multiple Sclerosis es_ES
dc.subject Esclerosis Múltiple es_ES
dc.title Multiple sclerosis progression: time for a new mechanism-driven framework es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:ar-repo/semantics/artículo es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil Fil: Kuhlmann, Tanja. University Hospital Münster. Institute of Neuropathology; Alemania. McGill University. Montreal Neurological Institute. Neuroimmunology Unit; Canadá.
dc.description.fil Fil: Moccia, Marcello. Federico II University of Naples. Department of Neurosciences. Multiple Sclerosis Clinical Care and Research Centre; Italia.
dc.description.fil Fil: Coetzee, Timothy. National Multiple Sclerosis Society; Estados Unidos.
dc.description.fil Fil: Cohen, Jeffrey A. Cleveland Clinic.ellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute. Department of Neurology; Estados Unidos.
dc.description.fil Fil: Graves, Jennifer. University of California. Department of Neurosciences; Estados Unidos.
dc.description.fil Fil: Marrie, Ruth Ann. University of Manitoba. Rady Faculty of Health Sciences. Max Rady College of Medicine; Canadá.
dc.description.fil Fil: Montalban, Xavier. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Multiple Sclerosis Centre of Catalonia and Department of Neurology-Neuroimmunology; España. ,
dc.description.fil Fil: Yong, V. Wee. University of Calgary. Hotchkiss Brain Institute; Canadá.
dc.description.fil Fil: Thompson, Alan J. University College London. Faculty of Brain Sciences; Reino Unido. Hospitals Biomedical Research Centre. NIHR University College London. UCL Queen Square Institute of Neurology. Department of Neuroinflammation. Queen Square Multiple Sclerosis Centre; Reino Unido.
dc.description.fil Fil: Reich, Daniel S. National Institutes of Health. National Institute of Neurological Disorders and Stroke. Translational Neuroradiology Section; Estados Unidos.
dc.relation.ispartofPAGINATION S1474-4422(22)00289-7
dc.relation.ispartofCOUNTRY Inglaterra
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE The Lancet. Neurology.
dc.relation.ispartofISSN 1474-4465
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

info:eu-repo/semantics/openAccess Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: info:eu-repo/semantics/openAccess

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik